MVIS US Listed Biotech 25 Index

The modified market cap-weighted index tracks the performance of the largest and most liquid US-listed companies that generate at least 50% of their revenues from biotechnology. The pure-play index contains only companies which are engaged primarily in research and development as well as production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. The MVIS US Listed Biotech 25 Index (MVBBH) has been licensed to underlie financial products with currently USD 349.49 million in assets under management.

Components

The MVIS US Listed Biotech 25 Index counts currently 25 components. The full list of the components with the respective weights is available below.

Items 1-25 of total 25
ComponentCountryWeight
AMGEN INCUS10.77%
GILEAD SCIENCES INCUS7.45%
CELGENE CORPUS6.90%
ALLERGAN PLCIE6.33%
IQVIA HOLDINGS INCUS5.39%
VERTEX PHARMACEUTICALS INCUS5.24%
INCYTE CORPUS4.90%
BIOGEN INCUS4.86%
EXACT SCIENCES CORPUS4.59%
BEIGENE LTD-ADRKY4.49%
REGENERON PHARMACEUTICALSUS4.20%
ALEXION PHARMACEUTICALS INCUS4.11%
ILLUMINA INCUS4.11%
BIOMARIN PHARMACEUTICAL INCUS3.91%
QIAGEN NVNL3.37%
NEUROCRINE BIOSCIENCES INCUS2.75%
SAREPTA THERAPEUTICS INCUS2.68%
GRIFOLS SA-ADRES2.67%
CHARLES RIVER LABORATORIESUS2.59%
ALNYLAM PHARMACEUTICALS INCUS2.38%
IONIS PHARMACEUTICALS INCUS2.05%
SEATTLE GENETICS INCUS1.69%
UNITED THERAPEUTICS CORPUS1.23%
BLUEBIRD BIO INCUS0.71%
NEKTAR THERAPEUTICSUS0.65%
Items 1-25 of total 25
Up